RxDoctor Payments Data

Raud Estep, MD

Family Medicine · Lafayette, INNPI 1497723605

Payments from drug & device makers

$485in general payments, 2019–2025

Across 30 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$131
  • Dexcom, Inc.$89
  • Novo Nordisk$70
  • Merck$36
  • E.r. Squibb & Sons, L.L.C.$26
  • Abbott$24
  • plus $110 from 8 others

What the payments were for

  • Food & beverage$47398%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$485 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$127,251
Medicare patients
381
Services billed
2,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$131,742
MounjaroTirzepatide108$125,602
OzempicSemaglutide86$108,013
RybelsusSemaglutide45$84,363
EliquisApixaban83$59,537
XareltoRivaroxaban50$48,577
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$26,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$17,296
Tresiba Flextouch U-100Insulin Degludec17$16,725
LinzessLinaclotide12$11,545
SymbicortBudesonide/Formoterol Fumarate15$7,881
Testosterone26$7,594
ShingrixVaricella-Zoster Ge/As01b/Pf32$7,116
Combivent RespimatIpratropium/Albuterol Sulfate12$5,706
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$70$192,376131 claims
Lilly USA, LLCMounjaro$14$125,602108 claims
AbbVieLinzess, Synthroid$16$13,12836 claims
AstraZenecaSymbicort$12$7,88115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →